Health and Healthcare

Why Biogen's Q2 Was So Great

biogen.com

When Biogen Inc. (NASDAQ: BIIB) released its second-quarter financial results before the markets opened on Tuesday, the biotech giant said that it had $9.15 in earnings per share (EPS) and $3.60 billion in revenue. The consensus estimates had called for $7.53 in EPS and $3.47 billion in revenue, and in the same period of last year, $5.80 in EPS and $3.36 billion in revenue were posted.

Multiple sclerosis revenues in the latest period, including $183 million in royalties on the sales of Ocrevus, increased 3% year over year to $2.4 billion.

At the same time, revenue growth was driven in part by the continued global launch of Spinraza, which contributed $488 million in revenues.

Biosimilars revenues, primarily driven by Imraldi, increased to $184 million compared to $127 million in the second quarter of 2018.

Looking ahead to the 2019 full year, the company expects to see EPS in the range of $31.50 to $32.30 and revenue between $14.0 billion and $14.2 billion in revenue. Consensus estimates call for $29.70 in EPS and $13.95 billion in revenue for the year.

Michel Vounatsos, Biogen’s CEO, commented:

Biogen delivered solid performance globally in the second quarter, and we believe we are on track for a strong year. We added four new programs to our pipeline this quarter, as we continued to diversify and build depth within neuroscience and pursue therapeutic adjacencies. Specifically, the acquisition of Nightstar Therapeutics has provided us with two potentially first-in-class mid- to late-stage gene therapy programs in specialty ophthalmology, and we initiated two new studies in our priority areas of multiple sclerosis and amyotrophic lateral sclerosis. We continued to allocate capital, and we remain focused on investing in the areas we believe have the highest potential return for shareholders.

Shares of Biogen traded up about 5% to $244.14 Tuesday, in a 52-week range of $216.12 to $388.67. The consensus price target is $253.00.


The Average American Is Losing Momentum On Their Savings Every Day (Sponsor)

If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4%1 today. Checking accounts are even worse.

But there is good news. To win qualified customers, some accounts are paying more than 7x the national average. That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.